AFT gains Australian registration for intravenous Maxigesic

AFT gains Australian registration for intravenous Maxigesic
Jenny Ruth
By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...

More Services

Creative solutions needed to keep NZ workers
Economy

Creative solutions needed to keep NZ workers

Robert Walters sees talent migration potentially getting worse in 2025.

‘Battle-hardened’ Trade Window eyes growth
Markets

‘Battle-hardened’ Trade Window eyes growth

The customs software minnow has weathered the storm. What next?

Pattrick Smellie 21 Nov 2024
Crimson big enough for ASX IPO: Beaton
Finance

Crimson big enough for ASX IPO: Beaton

A US market listing at a greater scale looks more likely.

Pattrick Smellie 06 Nov 2024
CoreLogic data suggests property market floor is nigh
Property

CoreLogic data suggests property market floor is nigh

Broad economic trends underpin the latest figures, CoreLogic's economist says.